Rusan Pharma Launches API Facility in Madhya Pradesh with INR 300 Cr Investment

The newly launched facility is designed to meet international regulatory guidelines, ensuring the highest level of compliance. With the production capability of 400 metric tonnes of APIs annually.

Global pharmaceutical player Rusan Pharma has launched its advanced API facility in Pithampur, Special Economic Zone (SEZ), Madhya Pradesh. The total investment over two phases will be up to INR 300 Cr.

The newly launched facility is designed to meet international regulatory guidelines, ensuring the highest level of compliance. With the production capability of 400 metric tonnes of APIs annually.

Additionally, the new facility will capitalise on the support and subsidies provided by the Madhya Pradesh state government. Further, the strategic location is expected to streamline business operations and export processes through the dry port.

Expressing his views, Dr Navin Saxena, Founder and Chairman, Rusan Pharma, said, "The new API facility in Pithampur will enable Rusan to significantly enhance our existing API capacity and ensure the security of supply of critical APIs to meet the growing demand for our addiction treatment and pain management products in India and globally"

Moreover, the new plant boasts five modular API manufacturing blocks with dedicated suites for finished API manufacturing. This grants the pharma company complete control over the quality of our products thereby reducing their dependency on imports.

This launch aligns with the pharma’s commitment to incorporate advanced automation and compliant software, incorporating paperless manufacturing, along with stringent environmental controls.

Further, this move will enable the company to produce essential medicines more affordably, expanding accessibility to a broader population.

Founded in 1994, by Vimal Pratap Jaswa, Rusan Pharma Ltd is a fully integrated global pharmaceutical company that specialises in the treatment of ‘Addiction and Pain Management’.

The company has a significant global presence, offering a complete range of products for de-addiction and pain management in countries across the globe including Europe, UK, Russia, CIS, South Africa, Mauritius, Nepal, and Myanmar.

Going forward the pharma giant plans to become an end-to-end value chain company in controlled substances. This means they want to be involved right from the cultivation of poppy to the extraction of opium-based alkaloids for making drugs, and also plan to set up clinics for treating addiction. In addition, Rusan Pharma aims to generate revenues of about INR 600 Cr over the next 2-3 years by expanding its footprint in the overseas market.

Recently, the Kotak Fund invested INR 1,600 Cr in Nimmagadda Prasad’s API biz. Reportedly, to support this acquisition, KSSF contributed $200 million in funding, a combination of structured debt and equity. Moreover, Deutsche Bank and DBS have also financed the acquisition. However, the exact figure of the transaction could not be ascertained.